ALB

118,652 patent compounds predicted against ALB, 82,919 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL854	0.64	4/20
Lamivudine (SCHEMBL33979)	1.00	3/20
Emtricitabine (SCHEMBL39708)	1.00	3/20
Betulinic Acid (SCHEMBL61767)	1.00	3/20
Lamivudine (SCHEMBL109675)	1.00	3/20
Emtricitabine, (+/-)- (SCHEMBL122131)	1.00	3/20
Lupeol (SCHEMBL148518)	0.72	3/20
Lupeol (SCHEMBL148519)	0.72	3/20
SCHEMBL97277	0.71	3/20
Betulin (SCHEMBL131739)	0.70	3/20
SCHEMBL588	0.69	3/20
SCHEMBL1268	0.62	3/20
Zalcitabine (SCHEMBL3598)	0.62	3/20
Troxacitabine (SCHEMBL18548)	0.60	3/20
SCHEMBL1390	0.58	3/20
SCHEMBL127212	0.58	3/20
SCHEMBL5821	0.53	3/20
SCHEMBL46293	0.46	3/20
Warfarin (SCHEMBL3689)	1.00	2/20
Bromoxynil (SCHEMBL19210)	1.00	2/20

Clinical trials — most relevant to ALB by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy	PHASE4	UNKNOWN
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer	PHASE4	RECRUITING
Albumin and Crystalloid Administration in Septic Shock	PHASE4	RECRUITING
A Study of Recombinant Human Albumin Injection to Treat Hypoalbuminemia in Cirrhotic Patients With Ascites	PHASE3	COMPLETED
Albumin Administration in Patients With Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis	PHASE3	COMPLETED
Phase II/III Clinical Trial of Recombinant Human Serum Albumin in Cirrhotic Patients With Ascites	PHASE2/PHASE3	COMPLETED
Phase II/III of Recombinant Human Serum Albumin	PHASE2/PHASE3	COMPLETED
Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study)	PHASE3	NOT_YET_RECRUITING
Albumin for Hepatocellular Carcinoma	PHASE3	UNKNOWN
Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy	PHASE3	COMPLETED
A Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe POTS	PHASE3	WITHDRAWN
Resuscitation With Albumin 5% in Dengue Haemorrhagic Fever	PHASE3	UNKNOWN
Phase II/III of Recombinant Human Albumin Injection	PHASE2	COMPLETED
Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis	PHASE2	COMPLETED
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement	PHASE2	RECRUITING
Fluid Resuscitation in Early Septic Shock	PHASE2	COMPLETED
Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC	PHASE2	NOT_YET_RECRUITING
Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects	PHASE1	COMPLETED
Recombinant Human Serum Albumin in Healthy Subjects	PHASE1	COMPLETED
The Effect of Albumin Supplementation on the Inflammatory and Oxidative Stress Markers in Septic Patients	EARLY_PHASE1	UNKNOWN
Recombinant Human Serum Albumin in the Treatment of AD (Alzheimer Disease) Exploratory Clinical Trials	EARLY_PHASE1	ACTIVE_NOT_RECRUITING
PROGNOSTIC ROLE OF SERUM ALBUMIN LEVEL IN RADIOLOGICAL PROGRESSION OF GONARTHROSIS: IS IT A BIOMARKER IN ITSELF? A BIOMARKER ASSOCIATED WITH SYSTEMIC INFLAMMATION?	nan	COMPLETED
Effect of Albumin Infusion on Oxidative Albumin Modification, Albumin Binding Capacity and Plasma Thiol Status	nan	COMPLETED
Coagulation Parameters With Albumin in Decompensated Cirrhosis (CoPA-D).	nan	COMPLETED
Effects of Maintaining Steady Albumin Levels (TAT 4) on Survival and Liver Related Complications in Cirrhosis With Ascites	nan	UNKNOWN
Albumin Infusion Targets on Mortality in Patients With Abdominal Sepsis	nan	COMPLETED
Nordic Cystectomy Study II - Albumin	nan	UNKNOWN
Efficacy of 5% Albumin v/s Plasmalyte in Combination With 20% Albumin for Fluid Resuscitation in Cirrhosis With Sepsis Induced Hypotension	nan	UNKNOWN
Post-Operative Use of Salt Poor Albumin Solution in Resuscitation of Orthotopic Liver Transplant	nan	UNKNOWN
Determination of Albumina as an Early Predictor of Postoperative Infections in Colorectal Surgery	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ALB binder may also engage these)

Protein	Name	Similarity
A6YF56	—	1.000	A6YF56 →
Q5NVH5	—	1.000	Q5NVH5 →
Q28522	—	1.000	Q28522 →
O35090	—	1.000	O35090 →
Q5XLE4	—	1.000	Q5XLE4 →
P49822	—	1.000	P49822 →
A2V9Z4	—	1.000	A2V9Z4 →
P14639	—	1.000	P14639 →
P02769	—	0.999	P02769 →
P08835	—	0.999	P08835 →
P49064	—	0.999	P49064 →
P35747	—	0.998	P35747 →
P07724	—	0.997	P07724 →
P02770	—	0.997	P02770 →
P19121	—	0.996	P19121 →
P49065	—	0.996	P49065 →
P21847	—	0.994	P21847 →
Q3MHN5	—	0.993	Q3MHN5 →
GC	Vitamin D-binding protein	0.992	landscape →
P02771	—	0.991	P02771 →
P28050	—	0.990	P28050 →
P53789	—	0.990	P53789 →
Q3T478	—	0.989	Q3T478 →
P21848	—	0.988	P21848 →
P14872	—	0.988	P14872 →
P04276	—	0.988	P04276 →
Q03156	—	0.988	Q03156 →
Q3SZ57	—	0.987	Q3SZ57 →
P49066	—	0.987	P49066 →
Q28789	—	0.987	Q28789 →